Global 3D Bioprinting Market is forecast to grow at high rate with CAGR of 19.3%

Global 3D Bioprinting Market is witnessing a high CAGR growth of 19.3% and is expected to reach USD 5.1 Bn by 2027

The global 3D bioprinting market is growing significantly due to increasing applications in medical procedures such as drug validation, living tissue recreation, and 3D bioprinting provide the generation of patient-specific tissue for precise tissue & targeted drug delivery of personalized medications. Moreover, majority of medical devices companies rely on 3D bioprinting for orthopedic implants which boost the growth of 3D bioprinting demand during the forecast period across the globe. Additionally, rising investments in the R&D by government and private companies is expected to propel the growth of 3D bioprinting demand during the forecast period. For instance, in November 2018, Aspect Biosystems (Canada) received USD 2.7 Mn from the Government of Canada’s Western Innovation Initiative (WINN) in the form of funds to carry out 17 projects in British Columbia in coming years. The total funding for the project was ~USD 20 Mn. This government initiative aimed to give rise to companies in British Columbia to grow and complete the project.

Rising government support in terms of funding is expected to fuel the growth of 3D bioprinting demand in the market. In addition, upcoming advances in the bioprinting is expected to lead the production of the high-throughput, resolution 3D bioprinters, more progressive & improved vascularization of bioprinted tissue, and generation of in vivo and in vitro tissue models is expected to fuel the growth of 3D bioprinting demand during the forecast period.

Moreover, 3D bioprinting hold the potential to the counterfeit biomedical devices, implants, prosthetics, organs, and tissues during the forecast period. Availability of specialized medical devices, surgical instruments hold the capacity of manufacturing quickly and cost effectively. Thus, additive manufacturing also known as 3D bioprinting, which is expected to create patient centric medical care and boost the growth of 3D bioprinting demand during the forecast period.

Covid-19 pandemic has affected the supply chain and production of pharmaceutical products across the globe. 3D bioprinting companies relocated their units near hospitals and transportation hubs to serve the rising need of the medical profession during the covid-19 outbreak. Moreover, 3D bioprinting companies has reallocated their capabilities to serve covid-19 cases and demonstrated their competitive advantage in the critical situation. Moreover, rising demand for covid-19 vaccines has created curiosity among researchers and scientists to accelerate the development of drug and vaccines through new technology for the safety testing. The accelerated demand for the medical devices and drug evaluation is expected to boost the growth of 3D bioprinting during the forecast period.

Global 3D Bioprinting Market by Region Outlook (Revenue, USD Million, 2021-2027)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Based on region, Asia-Pacific market is expected to witness the highest growth during the forecast period due to increase in research activities, increasing penetration of new entrants in the market, and growing adoption of stem cell therapy for research purposes. Moreover, emerging economies in region such as India and China are expected to provide the opportunities for key players in 3D bioprinting market. Besides, increasing demand for the 3D bioprinting in cosmetic surgeries and presence of less stringent regulatory policies when compared with developed regions are expected to fuel the growth of 3D bioprinting demand during the forecast period.

The Global 3D Bioprinting Market Segmentation:

Global 3D Bioprinting Market by Component Type Outlook (Revenue, USD Million, 2021-2027)

• 3D Bioprinters
  • Microextrusion Bioprinting
  • Magnetic 3D Printing
  • Inkjet 3D Bioprinting
  •  Others

• Bioinks
  • Synthetic Bioinks
  •  Hybrid Bioinks
  • Natural Bioinks

Global 3D Bioprinting Market by Applications Outlook (Revenue, USD Million, 2021-2027)

• 3D Cell Culture
• Drug Research
• Regenerative Medicine
• Clinical Applications
  • Skin
  • Bone & Cartilage
  • Blood Vessels
• Others

Global 3D Bioprinting Market by Materials Type Outlook (Revenue, USD Million, 2021-2027)

• Hydrogels
• Living Cells
• Extracellular Matrices
• Others

Global 3D Bioprinting Market by End Users Type Outlook (Revenue, USD Million, 2021-2027)

• Biopharmaceutical Companies
• Research Organization & Academic Institutes
• Hospital

Key Findings:

• Based on component, inkjet 3D bioprinting segment is expected to dominate the market during forecast period
• Based on applications, skin printing segment is expected to account for the highest market share during forecast period
• Based on materials, living cells segment is expected to dominate the market during the forecast period
• Based on end users, biopharmaceutical companies are expected to hold the largest market share during the forecast period
• Based on region, North America is expected to hold the largest market share during the forecast period. On the contrary, Asia-Pacific is expected to witness highest growth during forecast period

Company Profiles and Competitive Intelligence

The key players operating in the 3D bioprinting market are:

• Organovo Holdings, Inc.
• CELLINK
• Allevi Inc.
• Aspect Biosystems Ltd.
• EnvisionTEC GmbH
• Cyfuse Biomedical K.K.
• Poietis
• TeVido BioDevices
• Nano3D Biosciences, Inc.
• ROKIT Healthcare
• Digilab, Inc.
• regenHU
• GeSiM
• Advanced Solutions Life Sciences
• Advanced Biomatrix
• 3D Biotek
• 3D Systems
• Avita Medical
• Bespoke Innovations
• Autodesk
• EnvisionTEC
• Cyfuse Biomedical
• CMC Microsystems
• United Therapeutics
• DTM
• Bio3D Technologies
• Helisys Inc.
• InSphero AG
• BD Biosciences

Recent News:

• In March 2021, CELLINK (US) launched BIO MDX™ series that is next generation of bioprinters which is designed with high-throughput of bio-fabrication and precise 3D bioprinting that include biocompatible medical devices. Device has been specially designed to meet rising demand for advanced cell-based technologies. This launch is expected to illustrate the commitment for bringing new technologies to solve the pressing challenges in the life sciences. Product introduction is expected to leverage the synergies across the company by initiating the initial step for developing systems and bringing solutions that would bring the company close to provide patient care and create future of medicines.
• In September 2021, BICO’s (US) subsidiaries CELLINK(US), Visikol (US), and MatTek (US) collaborated to launch 3D bioprinting CRO by combining their expertise by providing comprehensive bioprinting services. The collaboration is expected to offer biomaterials and cell analysis. Using CRO the companies are expected to gain customer access to the offerings from the three companies. The combination of companies is expected to offer researchers a thorough bioprinting experience to the customers and this would help the parent company to gain customer base for their services.